Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory condit…
FAIL · Does not pass the screen
25.41 USD
Screen close, 2026-09-21 · not a live quote Last reviewed 15 days ago
Screened 2026-09-21 · the tape above runs as of 19:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 25.41 against the desk's fair-value range, base estimate 34.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price25.41 USD
Fair value34.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown25.41+0.0% to today
2026-09-08Read Accumulation26.88-5.5% to today
2026-08-07Read Markup23.12+9.9% to today ✓
2026-07-02Read Accumulation16.95+49.9% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Nurix Therapeutics, Inc. holds its Markdown at $25.41. The statistical read favours the buyers, held for 5 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 5 days
Price at the screen
$25.41
Valuation
N/A trailing · -23.61 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.80
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.10%
Below 33%
Interest-bearing debt is just 8.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
50.28%
Below 33%
Interest-bearing cash and securities are 50.3% of assets, above the one-third limit.
Fail
Receivables
35.89%
Below 49%
Money owed to the company is 35.9% of assets, under the 49% limit.
Pass
Revenue purity
26.16%
Below 5%
26.2% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Nurix Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 50% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 33.8% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +34% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
Developing a new cancer drug is like funding a marathon runner who has not even reached the starting line. Nurix focuses on small molecule therapies for oncology and inflammation, yet revenue has fallen 80% while losses remain total and return on equity sits at minus 80%. Analysts see upside to $34, but the business still burns cash with no approved products and an unknown moat.
The 45% gap to our fair value looks tempting on paper, yet opportunity rating stays at none. Negative forward earnings, zero profit margin and an early pipeline mean any valuation rests on future trial success that has not arrived. Ethical screen clears, but that alone does not create a durable business.
High failure rates in the clinic, repeated dilution risk and execution uncertainty keep us on the sidelines. The numbers show a company still far from cash flow, not a bargain in disguise. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NRIX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$25.41-5.5%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (17 analysts) rates it strong buy, with a mean price target of $30. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 16.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (17 analysts) rates it strong buy, with a mean price target of $30.
2026-08-07Markup · changed$23.12+36.4%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 36.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (17 analysts) rates it strong buy, with a mean price target of $30.
2026-07-18Accumulation$16.95+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (17 analysts) rates it strong buy, with a mean price target of $30.
2026-07-03Accumulation$16.95+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$16.95Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
